Bolandiol
Clinical data | |
---|---|
Other names | 19-Norandrostenediol; 19-Nor-4-androstene-3β,17β-diol; Estr-4-ene-3β,17β-diol; 3β-Dihydronandrolone |
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
ChemSpider |
|
UNII |
|
ChEBI |
|
ChEMBL |
|
CompTox Dashboard (EPA) |
|
Chemical and physical data | |
Formula | C18H28O2 |
Molar mass | 276.420 g·mol−1 |
3D model (JSmol) |
|
| |
InChI
|
Bolandiol (INN, also known as 19-nor-4-androstenediol, estr-4-ene-3β,17β-diol, or 3β-dihydronandrolone) is an anabolic-androgenic steroid (AAS) that was never marketed.[1] However, a dipropionate ester derivative, bolandiol dipropionate, has been marketed.[1][2] Bolandiol and its dipropionate ester are unique among AASs in that they reportedly also possesses estrogenic and progestogenic activity.[3][4]
Bolandiol is on the World Anti-Doping Agency's list of prohibited substances,[5] and is therefore banned from use in most major sports. It is a potential metabolic precursor to nandrolone.[6] However, several clinical studies have concluded that bolandiol does not alter strength, body composition, or exercise performance.[7][8]
See also
- 4-Androstenediol
- 19-Nor-5-androstenediol
- 19-Nor-5-androstenedione
- Bolandione (19-nor-4-androstenedione)
- Bolenol (17α-ethyl-19-nor-5-androstenol)
References
- ^ a b Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 899–. ISBN 978-1-4757-2085-3.
- ^ Hyde TE, Gengenbach MS (2007). Conservative Management of Sports Injuries. Jones & Bartlett Learning. pp. 1100–. ISBN 978-0-7637-3252-3.
- ^ Action QA, ed. (9 January 2012). Hormones: Advances in Research and Application (2011 ed.). ScholarlyEditions. pp. 59–. ISBN 978-1-4649-2242-8.
- ^ Attardi BJ, Page ST, Hild SA, Coss CC, Matsumoto AM (February 2010). "Mechanism of action of bolandiol (19-nortestosterone-3beta,17beta-diol), a unique anabolic steroid with androgenic, estrogenic, and progestational activities". The Journal of Steroid Biochemistry and Molecular Biology. 118 (3): 151–61. doi:10.1016/j.jsbmb.2009.11.008. PMC 2831543. PMID 19941958.
- ^ "The World Anti-Doping Code: The 2012 Prohibited List" (PDF). World Anti-Doping Agency. Archived from the original (PDF) on 2012-05-13. Retrieved 2012-07-17.
- ^ Dehennin L, Bonnaire Y, Plou P (January 2002). "Human nutritional supplements in the horse: comparative effects of 19-norandrostenedione and 19-norandrostenediol on the 19-norsteroid profile and consequences for doping control". Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 766 (2): 257–263. doi:10.1016/S0378-4347(01)00506-0. PMID 11824814.
- ^ Van Gammeren D, Falk D, Antonio J (May 2001). "The effects of supplementation with 19-nor-4-androstene-3,17-dione and 19-nor-4-androstene-3,17-diol on body composition and athletic performance in previously weight-trained male athletes". European Journal of Applied Physiology. 84 (5): 426–431. doi:10.1007/s004210100395. PMID 11417430. S2CID 13129479.
- ^ van Gammeren D, Falk D, Antonio J (September 2002). "Effects of norandrostenedione and norandrostenediol in resistance-trained men". Nutrition. 18 (9): 734–737. doi:10.1016/s0899-9007(02)00834-1. PMID 12297208.
- v
- t
- e
(incl. AASTooltip anabolic–androgenic steroid)
ARTooltip Androgen receptor antagonists | |||||
---|---|---|---|---|---|
Steroidogenesis inhibitors |
| ||||
Antigonadotropins |
| ||||
Others |
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
- See also
- Androgen receptor modulators
- Estrogens and antiestrogens
- Progestogens and antiprogestogens
- List of androgens/anabolic steroids